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BACKGROUND: Projections of cancer incidence are important for planning health services and to provide a baseline for assessing
the impact of public health interventions.
METHODS: Rates estimated from smooth function age–period–cohort modelling of cancer incidence data from Great Britain 1975 to
2007 are extrapolated to 2030 and applied to UK population projections. Prostate and breast cancer projections take into account
the effect of screening.
RESULTS: Overall rates of cancer are projected to be stable over the next 20 years, but this masks individual changes. In both sexes,
age-standardised rates of cancers of the stomach, larynx, bladder and leukaemia are projected to fall by X1% per year, whereas
cancers of the lip, mouth and pharynx (ICD-10 C00-C14) and melanoma are projected to increase by X1% per year. The growing
and aging populations will have a substantial impact: numbers of cancers in men and women are projected to increase by
55% (from 149169 to 231026) and 35% (from 148716 to 200929), respectively, between 2007 and 2030. The model used yields
similar results to those of Nordpred, but is more flexible.
CONCLUSION: Without new initiatives for smoking and obesity reduction, the number of cancers in the United Kingdom will increase
substantially reflecting the growing and aging populations.
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Quantifying the future burden of cancer incidence and mortality,
in terms of expected numbers of cases and deaths, or rates of
disease, is important in optimising the allocation of resources for
screening, diagnostic, therapeutic and palliative services and to
provide a baseline from which the success of future interventions
can be judged (Bray and Møller, 2006).
The future number of cases (or deaths) is a consequence of two
components of change; the evolution of the size and age structure
of the population (demographic component) and changes in the
rates of disease. The latter component is generally evaluated by
some form of projection – likely future trends are estimated on the
basis of those observed in the past. A distinction should be made
between what we refer to as ‘projections’ and ‘predictions’. We use
the term ‘projections’ for the extrapolation of observed trends in
incidence rates that do not explicitly take into account expected
changes in factors influencing risk (in a positive or negative way).
By contrast, we use ‘predictions’ to be statements about the
future that take into account all known trends and likely future
changes in risk factors. Predictions necessarily involve some sort
of modelling: incorporating data on postulated future change
in factors that affect risk, the components of the population likely
to be involved, the size of the effect (relative risk) and latency
between exposure and outcome.
Several statistical methods have been used to make projections
of future cancer burden. While short-term projections may assume
continuation of past rates of change – generally within specific age
groups – projections over the longer term need to model more
complex interactions, incorporating the past components of
change due to the effects of age, calendar period and birth cohort,
and making explicit assumptions about the extent to which past
changes are likely to operate into the future (Møller et al, 2003;
Sedjo et al, 2007; Olsen et al, 2008). In the United Kingdom,
previous studies have used such models to generate cancer
mortality projections up to the year 2025 (Olsen et al, 2008), and
cancer incidence projections up to the year 2020 for England
(Møller et al, 2007). In this paper, we use data on the incidence of
cancer in Great Britain (GB: England, Scotland and Wales) between
1975 and 2007 to make projections of the future rates of 28 types of
cancer in the United Kingdom up to 2030, and estimate the
corresponding future burden in terms of numbers of cases, using
national population projections. Compared with the paper by
Møller et al (2007), we use data for the United Kingdom (England,
Scotland, Wales and Northern Ireland) rather than England,
include data for 2004–2007 and make projections for prostate and
bladder cancers (which they avoided) and use methodology that
takes into account changes in breast screening when modelling
breast cancer rates.
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Data on the incidence of 28 cancers (individual sites or groups of
sites, defined by ICD-10 codes), in terms of numbers of cases and
population at risk, by 5-year age group and sex, in GB (England,
Scotland and Wales) for the period 1975–2007 were provided by
Cancer Research UK, who in turn received the data from the UK
Association of Cancer Registries. National population projections
(2008 based) for the United Kingdom (GB plus Northern Ireland)
by sex, 5-year age group and year, from 2008 to 2030, were
obtained from the population projections of the Office for National
Statistics (ONS, 2009).
The cancer incidence rates were modelled using age-period-
cohort (APC) models and extrapolated out to 2030. The basic APC
model was
lðage;periodÞ¼gffAðageÞþfPðperiodÞþfCðcohortÞg;
where l is the incidence rate as a function of age and calendar
period, g is a ‘link’ function and fA, fP and fC are functions of
age, period (year of incidence) and cohort (year of birth,
i.e., cohort¼period-age), respectively. Here the link function, g,
is either the exponential function or the power 5 function (i.e.,
g(x)¼x
5 as used by Møller et al (2002)), and the functions fA, fP
and fc are either step functions on 5-year intervals or natural cubic
splines. Whereas step-functions are more commonly used, cubic
splines provide much greater flexibility and are more realistic if
one believes that changes over time occur smoothly rather than in
sudden jumps. Flexible additive models were popularised by
Hastie and Tibshirani (1990) and cubic splines have been used
earlier in APC models by Sasieni and Adams (1999, 2000) and
more recently by Cartensen (2007). Additionally, there is a
question regarding how one should extrapolate the model beyond
the most recent period. Although the issue is most apparent in
terms of deciding on what fP should be for a future period, the
linear dependence between age, period and cohort means that
there is no unique definition of a model in which the fP is kept
constant for future periods. When modelling, using cubic splines,
we absorb the linear trends in period and cohort over the timespan
with observed data into a drift component and then attenuate the
drift into the future. The idea of attenuating or dampening the drift
comes from the belief that past trends will not continue forever
and was seen to be valuable empirically for making future
predictions by Møller et al (2002). We have reduced the drift by
8% each year beyond the period of observations. The factor 0.92
(¼1–0.08) was chosen so that the drift after 8 years will be
approximately half of what it is during the observation period.
(Møller et al (2002) used arithmetic dampening: 25% in years 1–5,
50% in years 6–10, 75% in years 11–15. Our geometric dampening
gives corresponding amounts of 21.6%, 48.3% and 65.9%.)
For cancers of the prostate and breast, the models were fitted
to a modified data set in order to take account of the changes in
incidence attributable to the increased use of PSA testing and the
introduction of breast screening, respectively. For prostate, data
from the period prior to extensive use of PSA testing (1975
to 1991) were used to fit an APC model (with a logarithm link)
to predict rates in the absence of extensive PSA testing for
2004–2007. These predicted rates were then used to calculate age-
specific observed/predicted ratios. The observed counts for 2004,
2005, 2006 and 2007 were divided by these ratios in order to obtain
an estimate of what the counts would have been in the absence of
the increased use of PSA testing. Predictions for 2008–2030 were
made by fitting APC models to the data for 1975–1991 and the
modified data for 2004–2007 and multiplying the model projec-
tions by the previously obtained observed/predicted ratios.
Our projections are thus based on the assumptions that the level
of PSA testing in the future will be similar to that in 2004–2007.
Our methodology separates the underlying trends in prostate
cancer incidence from the effect of PSA testing, and can thus be
used to make predictions that include explicit assumptions
regarding future rates of PSA testing. Similarly, for female breast
cancer we used data from before screening was offered to a
particular age-group to predict what would have happened to rates
once the programme had reached a steady state in that age group,
and used the ratio of observed to predicted rates to adjust all
subsequent data before making predictions until 2030. Explicitly,
incidence rates from the following age groups and periods were
assumed to have been affected by the introduction of screening
and not used in the model building: age group 50–64 years during
1989–1996; age group 65–69 years during 1990–1997 and 2003–
2007; age group 70–74 years during 2004–2007.
In order to make projections for ‘all cancer’, we fitted models to
17 different cancer sites in males plus one for ‘other cancer in
males’ and added the results. Similarly we modelled 19 different
sites in females plus ‘other’.
A function was developed in Stata to fit the model to the
incidence of cancer in individual years (for the 33-year period
from 1975 to 2007), and 5-year age groups (0–4, 5–9, y, 80–84,
85þ) by sex. This function was used in Stata version 10. The
primary projections presented here are based on the power-5 ‘link’
function and natural cubic splines for the functions of age, period
and cohort. Other functions were used to study the sensitivity of
the results to these constraints. The European standard population
(Waterhouse et al, 1976) was used for age standardisation.
To estimate the number of cases occurring in the population of
the United Kingdom in the years 1984, 2007 and 2030, the number
of cases in GB in each 5-year age group was multiplied by the ratio
of the age (and sex)-specific populations in the United Kingdom
and GB. We did not use UK rates, as incidence rates for Northern
Ireland are only available since 1993. Population estimates and
projections for the United Kingdom and GB (by sex and 5-year
age groups) were obtained from the Office of National Statistics
(ONS 2009). The rates were converted to numbers of cases for the
United Kingdom by multiplying by the ratio of the respective
populations. The underlying assumption is that the rates (and past
trends) for the United Kingdom were not significantly different
from those of GB (the population of which was 97.1% of that of the
United Kingdom in 2007).
Comparisons, for all sites other than breast and prostate, of our
cubic spline projections were made with those using step functions
in the Nordpred software (Møller et al, 2002) with the
R-statistical package. For each site–sex combination and each
5-year age group (age 50–84 years) and 5-year period, we
calculated the absolute difference between the two projections,
and compared this with the mean of the two projections.
RESULTS
Overall projected rates and numbers
Trends (1984–2007) and projections (2008–2030) of age-standard-
ised cancer incidence rates by sex and age group (10–24, 25–49,
50–64, 65–74, 75þ and all-ages) for all sites combined are shown
in Figure 1. The dots represent observed rates. The solid lines are
the projections based on the exponential link and the dotted lines
are the projections based on the power-5 link function. Note that
the jump from the observed rate for males aged 75þ years in 2007
and the projected rate for 2008 is due to the modelling of prostate
cancer for which the projections were made from a 2004–2007
base. Table 1 shows age-standardised incidence rates and numbers
of cancers for individual cancer sites, and for all cancers combined
for 1984, 2007 and 2030. The rates for 1984 and 2007 are the
observed GB rates. Those for 2030 are based upon the projections
using the power-5 model. For all years, the UK numbers
are estimated by applying the UK population to the age-specific
GB rates.
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sites by sex in GB have increased since 1984. For both males and
females, the ASRs are projected to level off with a 1.0% fall (from
2007 to 2030) in males and 1.9% fall in females.
Figure 2 shows trends and projections for 17 different cancers
shown (separately for male and female). The graphs are arranged
so that those with similar scales on the y-axis (incidence rates) are
in the same panel. As before, the dots represent observed data and
the lines represent the model fits (dotted line for power-5, solid
line for exponential). For all cancers apart from breast and
prostate, the model fits during the observed period (1975–2007)
are also plotted. It is seen that in most cases, the fit to the observed
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Figure 1 Trends and projections of cancer incidence rates (all cancers excl NMSC) for males and females in Great Britain.
Table 1 Age-standardised rates and numbers of specific cancers in men and women in 1984, 2007 and 2030
Males Females
Age std rates
(per 100000) Number of cases
Age std rates
(per 100000) Number of cases
Change
2007–30
Change
2007–30
Change
2007–30
Change
2007–30
Type 1984 2007 2030 Total Annual 1984 2007 2030 Total Annual 1984 2007 2030 Total Annual 1984 2007 2030 Total Annual
Oral 7.0 10.9 13.6 25% 1.0% 1917 3585 6276 75% 2.5% 3 4.6 5.5 21% 0.8% 1113 1819 2962 63% 2.1%
Oesophagus 9.9 14.4 13.9  4%  0.2% 2819 5231 7982 53% 1.9% 5.2 5.5 4.5  18%  0.9% 2244 2738 3400 24% 0.9%
Stomach 27.6 13.1 8.8  33%  1.7% 7936 4977 5656 14% 0.6% 12.1 5.4 4.0  26%  1.3% 5393 2768 3206 16% 0.6%
Colon 28.0 33.1 31.4  5%  0.2% 7971 12480 19865 59% 2.0% 23.4 24.1 23.8  1%  0.1% 9904 11643 17113 47% 1.7%
Rectum 21.9 23.2 20.8  10%  0.5% 6232 8419 12046 43% 1.6% 12.4 13.2 14.1 7% 0.3% 5110 5899 8940 52% 1.8%
Colorectal 49.9 56.2 52.3  7%  0.3% 14203 20899 31897 53% 1.9% 35.8 37.3 38.1 2% 0.1% 15014 17542 26279 50% 1.8%
Liver 2.6 5.9 7.5 27% 1.0% 747 2155 4185 94% 2.9% 1.3 2.7 2.6  2%  0.1% 506 1259 1871 49% 1.7%
Pancreas 12.1 10.1 10.0  2%  0.1% 3458 3739 5950 59% 2.0% 7.8 8.0 8.3 4% 0.2% 3353 3951 5979 51% 1.8%
Larynx 6.4 5.3 4.1  22%  1.1% 1784 1833 2105 15% 0.6% 1.1 0.9 0.7  27%  1.4% 381 356 360 1% 0.0%
Lung 107.2 59.3 54.6  8%  0.4% 31157 22329 32570 46% 1.7% 31.4 37.6 40.2 7% 0.3% 11892 17160 24630 44% 1.6%
Melanoma 3.7 14.6 22.3 52% 1.8% 987 5010 10939 118% 3.5% 6.2 15.4 23.4 52% 1.8% 1939 5713 10884 91% 2.8%
Breast 79.8 120.3 111.5  7%  0.3% 26600 45758 57442 26% 1.0%
Cervix 15.5 8.3 7.5  10% 0.5% 4669 2823 2828 0% 0.0%
Corpus Uteri + NOS 13.3 19.3 20.0 3.5% 0.1% 4556 7531 10913 44.9% 1.6%
Ovary 16.4 17.1 12.4  28%  1.4% 5501 6750 6480  4%  0.2%
Kidney 8.7 14.5 18.5 28% 1.1% 2432 5145 9772 90% 2.8% 4.0 7.3 8.6 18% 0.7% 1460 3061 5040 65% 2.2%
Bladder 29.3 19.0 15.9  16%  0.8% 8409 7319 10523 44% 1.6% 7.9 5.4 4.7  13%  0.6% 3220 2832 3568 26% 1.0%
Prostate 40.5 97.2 104.8 8% 0.3% 11714 36083 61089 69% 2.3%
Testis 4.2 6.6 6.1  8%  0.4% 1163 1994 2025 2% 0.1%
Brain + CNS 7.1 8.0 7.1  12%  0.6% 1928 2654 3102 17% 0.7% 4.9 5.6 5.0  10%  0.5% 1500 2015 2296 14% 0.6%
NHL 9.8 16.8 17.1 2% 0.1% 2736 5905 9141 55% 1.9% 6.7 11.9 10.1  15%  0.7% 2438 5023 6243 24% 1.0%
Myeloma 4.6 5.9 5.1  14%  0.6% 1305 2199 3115 42% 1.5% 3.3 3.9 3.3  15%  0.7% 1382 1824 2293 26% 1.0%
Leukaemia 10.5 11.6 9.1  22%  1.1% 2934 4092 5274 29% 1.1% 6.6 7.0 5.4  23%  1.1% 2509 2949 3428 16% 0.7%
All other sites 38.6 39.0 33.8  13%  0.6% 10928 14022 19444 39% 1.4% 30.78 33.6 34.2 2% 0.1% 11987 14844 20832 40% 1.5%
All cancer 379.6 408.5 404.6  1.0% 0.0% 108556 149169 231026 55% 1.9% 293.0 356.9 350.0  1.9%  0.1% 107658 148716 200929 35% 1.3%
Abbreviations: CNS¼central nervous system; NHL¼non-Hodgkin’s lymphoma; NOS¼not otherwise specified.
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Figure 2 Observed and projected cancer incidence rates for various cancers. Rates are age standardised within each of the five age-bands.
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noted that the differences between the exponential and the
power-5 model fits (to the observed data) are generally small,
but that the projections are more different the further
one goes in to the future. The only site for which the short-
term (i.e., 1–9 years) projections by the two models are not
extremely similar is prostate cancer (particularly in the age
group 65–74 years). For male lung cancer, the attenuation of
the decreasing rates is seen to be particularly strong for the
power-5 model.
There is a projected decrease in age-standardised incidence rates
for several sites between 2007 and 2030, with annual declines of 1%
or more for stomach, larynx, bladder, ovary and leukaemia.
Conversely, ASRs are projected to increase at rates of 1% or more
annually for cancers of the oral cavity, liver (males only),
malignant melanoma and kidney (males only).
Age-specific trends
These overall summary figures disguise some interesting variations
in the projected rate of change over time, and between age groups.
For instance, the large increases in incidence of cancer of the ovary
up to around the year 2000 have been reversed in the last 5–6
years, and this decline is projected to continue into the future
(Figure 2E). On the other hand, the current steep increase in
incidence of cancer of the corpus uteri (primarily endometrial
cancer) is projected to continue, before peaking around the year
2012 for women aged 65–74 years and a few years later for those
over 75 years (Figure 2D). It is noted that the fit of the APC model
to the observed rates for cancer of the corpus uteri is poor. (The
lines do not run through the dots in the age groups 50–64 or
75þ). For this reason, the projected down-turn in ages 65–74 and
75þ years must be viewed with some caution. For breast cancer,
the currently observed decrease in incidence in the age group 50–
64 years is projected to continue into the future, while the recent
increase at ages 65–74 years is projected to continue for another 7
or so years, before reversing (Figure 2I). The results for prostate
cancer vary somewhat depending on whether one uses an
exponential or a power-5 ‘link’ in the model, but, in general,
rather modest increases are projected in all age groups, subsequent
to the very brisk increases observed following the introduction of
PSA testing in the mid early 1990s (Figure 2K).
Effect of an increasing and ageing population
There is projected to be almost no change in the overall incidence
rates of cancer (for all cancers combined) in the 23-year period
2007–2030: the age-standardised incidence is projected to decrease
by  1.0% (equivalent to an average annual change of  0.04%) in
males and 1.9% ( 0.08% per year) females (Table 1). However,
because of the increase in the size of the population and ageing, the
number of cases is projected to increase for practically all types of
cancer, even for those with decreasing rates. The projected
increase in population size is 16% (61.0 million in 2007 and 70.7
million in 2030) for the United Kingdom. The proportion of elderly
persons in the population is increasing at a faster rate: from 16%
aged 65 years or more in 2007 to 22% in 2030; the proportion of
very elderly (85 or older) is expected to increase from 4.5% to 7.6%
over the same time period. In 2007, 100672 (67.4%) cancers in men
and 87214 (58.7%) in women were in those aged 65 plus years; in
2030, we project that there will be 176224 (76.2%) male and
135784 (67.5%) female cancer patients over age 65 years. In terms
of absolute numbers at all ages, the largest increase is in cancers of
the breast (11684 (26%) more cases in 2030 than in 2007) and
prostate (25006 (69%) more cases in 2030 than in 2007).
Figure 3A shows, for all cancers combined, the percentage
change between 2007 and 2030 in terms of ASRs, crude incidence
rates and numbers of cases. The change in ASRs approximates to
the change in risk, while the change in crude rates includes, in
addition, the effects of an ageing population. A further component,
as represented by the difference between the increase in crude
rates and that in the number of cases, is due to the increase in size
of the population.
Figure 3B shows the equivalent changes (in ASR, crude rate and
numbers of cases) for cancers of the prostate and breast. The
ASR of breast cancer is projected to fall by 8% between 2007 and
2030, while, despite the overall decline in risk, there will be a small
increase in the crude rate (6%) because of population ageing.
Population ageing makes the largest contribution to the projected
increase in the number of prostate cancer cases.
Figure 4 shows the proportionate distribution of different
cancers among the totals in 1984, 2007 and 2030. For females, the
rank order and percentage distribution change rather little over
time; the biggest differences being the increase in melanoma and
the decrease in stomach and cervical cancers. For males, however,
there has been a marked change. Lung cancer, by far the most
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Figure 3 Projected change in age-standardised rates, crude rates and numbers of cases from 2007 to 2030 (as percentages of the 2007 value).
(A) All cancer (by sex), (B) prostate cancer (males) and breast cancer (females).
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position (12% of male cancers), while prostate cancer now
comprises 29% of the total, having comprised only 11% of the
total in 1984. Stomach cancer, the fifth most common type of
cancer in 1984 no longer figures in the top 10 (it ranks 12th, with
o2% of the total), and melanoma (14th with just under 1% of male
cancer in 1984) is predicted to become the fourth most common
male cancer accounting for 4.6% of cases in 2030.
Comparison with Nordpred predictions
We also used the Nordpred package (with a power-5 link and
5-year step functions for age, period and cohort) to project
rates until 2023–2027. Comparison of 2052 age–sex–site–period-
specific projections (for all sites other than breast and prostate,
for ages 40þ years for all sites except for testis, and for ages
15–79 years for testis) were made (Table 2). The median of the
observed absolute differences increased from 9% for 2008–2012 to
14% for 2023–2027. The 95th percentile (i.e., the 488th largest of
the 513 comparisons in each 5-year calendar period) of the
distribution of disagreement was about four times greater than
the median (Table 2).
These results can be compared with those obtained by using the
data until 2002 in Nordpred to predict results for 2003–2008 and
comparing these with the observed data. Here the median absolute
disagreement was 7% and the 95th percentile 28%.
DISCUSSION
The observed data were annual incidence rates, for GB, by cancer
site, sex and 5-year age group from 1975 to 2007. The rates were
converted to numbers of cases for the United Kingdom by
multiplying by the ratio of the respective populations. Compared
with the actual incidence (number of recorded cases) in the United
Kingdom in 2007, the difference between observed and modelled
numbers of cases (using GB rates applied to the UK population)
was o1.5% for all sex/site combinations. In Table 1, we present the
projected changes in ASRs and in the numbers of cases of cancer
between 2007 and 2030. These can be used to split the change in
numbers between changes due to changing rates and changes due
to changing population. Thus, for instance, the 11% increase in
male stomach cancer cases is accompanied by a 33% fall in rates,
so that the effect of the population change is to increase numbers
by 66% (¼[100þ11]/[100 33] 1).
We have deliberately shown results on a linear rather than a
logarithmic scale because of the greater uncertainties in predicting
cancers in the young. For ovarian cancer, for instance, cancers in
young women are likely to be germ cell with very different risk
factors from epithelial cancer in older women; therefore, there is
no reason to suspect that cohort effects seen in those aged 15–29
years will carry forward to ages 35–49 years. Rates of melanoma,
ovarian cancer, endometrial cancer (corpus uterus) and testicular
cancer (not shown in Figure 2) are all non-negligible in those aged
25–49 years, and our model is seen to fit these observed data well.
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Table 2 Agreement between our (spline) model projections and those
of the Nordpred (step function) model
Period
Median percentage
absolute disagreement
95th percentile
absolute disagreement
2008–2012 9 35
2013–2017 10 40
2018–2022 10 37
2023–2027 14 66
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used if the interest was specifically on rates in the population in
this age group.
Future predictions depend on multiple assumptions, but the
basic premise is that past trends, affecting as they do the risk of
cancer in specific generations and/or time periods, will be carried
forward into the future. We modified this basic assumption in one
important respect – we attenuated the ‘drift’ component of the
observed changes in rates by 8% each year; thus in 2017–2018
years the annual drift is just 43% of what it was between 1975 and
2007, and by 2030 it was just 15%. The idea of attenuating the drift,
so as not to assume that increases or decreases continue forever,
was proposed and shown to be empirically useful by Møller et al
(2002), although whereas they used arithmetic damping, we chose
to use a geometric damping.
We compared our results with those based on projections using
the Nordpred package and its default power-5 link. The Nordpred
package requires input of past data for 5-year time periods, and
produces projections for periods of the same duration. The ‘drift’
component in Nordpred is reduced by 25% for each 5-year period
after the first. The results are a little different from those based
on our modelling using single years of observation, and the
magnitude of the deviation is similar to that seen when current
observed incidence rates are compared with those projected from
past data using Nordpred. We also allow the reader to compare our
model projections using power-5 and exponential link functions.
The latter is used for comparison because it is the default for
Poisson regression and because the age and period effects can be
interpreted as relative risks. It is not used for the main projections
because it can lead to extreme results, as the model is extrapolated
further into the future. It is of course impossible to judge in
advance which of the many projections (by sex, age group and
cancer site) will prove to be the more accurate.
The uncertainty associated with these predictions does not
concern sampling error (which would be small when based on the
relatively large numbers of cases under study), but the unquantifiable
bias when trends in some cancers behave in a manner that is incon-
sistent with the assumptions of the statistical analysis of past rates.
The projected numbers of cases are also dependent on reason-
able population projections. In this study, we used the 2008-based
population projections prepared by the Office for National
Statistics (ONS, 2009).
In the 24-year period 1984 to 2007, the overall age-standardised
incidence rate for cancer has increased in GB in both sexes,
although in the most recent 10-year period (1998–2007) they have
remained fairly constant (Figure 1). Male rates increased slightly
but have now returned to those of the late 1990s level. Female rates
have increased slightly (by around 3%). Future projections suggest
that the decline in male rates will continue, whereas rates in
women will peak, then start to decrease during the current decade
(2010–2019). The reduction in smoking prevalence has been
associated with declines in lung cancer rates in males throughout
the period, and, from around 2004 in females (Cancer Research
UK, http://info.cancerresearchuk.org/cancerstats/projections/lung/
females/, accessed December 2010). Our projections implicitly
assume that the reduction in smoking will continue, but do not
explicitly model smoking rates or take account of the most recent
changes in smoking prevalence. Indeed, changing rates of smoking
over the last decade will continue to affect lung cancer rates
into the next decade due to the cohort effect of smoking cessation
– ex-smokers have lower rates of lung cancer compared with
current smokers even (particularly) many years after cessation.
Nevertheless, whereas the reduction in male smoking in the United
Kingdom in the last quarter of the twentieth century was dramatic,
the more recent changes have been more modest and while the
rates of lung cancer are predicted to continue to fall, the numbers
will begin to increase (Table 1) as the population grows and ages.
Similarly, we do not consider the likely impact of colorectal
screening, HPV vaccination or of accelerated changes in obesity.
The predicted impact of fecal occult blood testing on colorectal
cancer incidence is small, as this form of screening is intended
primarily to diagnose cancer early. Nevertheless, the lead time
from screening will change the age-specific rates (Parkin et al,
2008), and with the introduction of flexible sigmoidoscopy it is
likely that the bowel screening programme will result in a
noticeable fall in the incidence of distal cancers. The impact of
HPV vaccination (introduced in women aged 12–18 years in 2008)
on cancer rates by 2030 will be quite small, as the total burden of
HPV-related cancers by age 40 years is small relative to the lifetime
burden of cancer in women.
After a long period of increasing incidence, age-standardised
incidence rates of breast cancer have begun to decline since 2005,
and this trend is projected to continue, reflecting in particular
declines in the age group 55–64 years. Some (if not all) of the
decline in breast cancer in this age group is undoubtedly due
to the substantial reduction in the use of HRT in recent years
(Parkin, 2009).
Other notable changes in rates include the continued steady fall
in stomach cancer in both men and women; the increase in
number of rarer cancers including melanoma, non-Hodgkin’s
lymphoma, kidney, liver and orophaynx in both men and women;
the increase in oesophageal cancer particularly in women; and the
increase in cancer of the corpus uterus. Although it is not possible
in a paper such as this to consider in detail the likely reasons
for past changes in rates of particular cancers or the likely impact
of changes to the health service over the next decade, the standard
approach for obtaining projections at any site can be used as a
basis for more detailed epidemiological study of such trends one
site at a time.
Møller et al (2007) published projections of cancer incidence for
England, for the period 2004–2020, based on observed rates in
1974–2003, using the Nordpred package. Although incidence rates
in men were projected to decline by 7% between 2001 and 2020
(driven largely by the declining rates of lung cancer), female rates
were projected to increase by the same amount, with significant
increases in the risk of breast cancer in particular. Apart from the
somewhat different populations studied (our projections were
based on rates from GB, not just England (86.2% of the British
population in 2007)), the availability of 4 years additional data
(2004–2007) and the slight differences in methodology, there are
two important sources of difference. First, Møller et al ‘projected’
the future incidence of cancer of the prostate by assuming
that rates would remain at the level observed in 1999–2003.
This almost certainly results in an estimate of future burden of
cancer of the prostate that is too low, and, as this cancer accounted
for almost one-quarter of all new cancer cases in men in 2007, an
underestimate too of the overall cancer burden. There is
considerable uncertainty in predicting prostate cancer incidence,
which is being driven not only by an inherent increase in the risk
of the disease, but also by the over-diagnosis (and over-treatment)
as a consequence of testing with PSA. There is little information
available on the extent of PSA testing in the United Kingdom. In
Scotland, the PSA testing first came into use in 1989, and the rate
of testing accelerated rapidly after 1991 (Brewster et al, 2000); the
slowly increasing rates of incidence in the United Kingdom greatly
accelerated at this time (Figure 2K). We have attempted to capture
the underlying increase in incidence (pre-testing) and assumed a
testing effect remaining as it was in 2004–2007. This is of course
almost certainly wrong, but, equally certainly, likely to provide a
more realistic future estimate than the assumption of no change, as
we do take into account the underlying increase in rates and we
believe that PSA testing, which is currently much less common
than in the USA, will most likely increase. Second, Møller et al
(2007) projected forward the trends in breast cancer incidence
observed in 1994–2003. The changes in incidence in recent years due
to patterns of breast cancer screening by age, and the decrease in use
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increase in incidence rates (B1% annually) is almost certainly
too pessimistic. In our prediction, the age-standardised incidence
for breast cancer will decline by 8% between 2007 and 2030.
Projections of cancer incidence, although inherently subjective
and unreliable, do provide a necessary baseline for future planning
of cancer resources and against which preventive interventions
can be judged. The methodology used here minimises the
subjectivity and provides a framework for such planning.
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